Here, patients age ≥ 18 with IDH1 mutated high-risk MDS or AML are enrolled in one of three cohorts (cohort one: ivosidenib plus venetoclax 400 mg, cohort two: ivosidenib plus venetoclax 800 mg, and cohort three: ivosidenib plus venetoclax 400 mg and AZA. Here, IDH1 is linked to acute myeloid leukemia.